New antibiotic and method for developing it exploits microbes' natural environment
the ONA take:
Researchers have discovered a powerful new antibiotic, teixobactin, using an unusual method. Teixobactin was tested in mice and easily cured severe infections, with no side effects.
Testing in humans will not begin for approximately 2 years, according to the researchers; therefore, its safety and effectiveness are not known at this time.
Even if the drug passes all the tests, it may not be available for 5 or 6 years. Importantly, the researchers are excited about the method used to produce this antibiotic because it has the potential to lead to the discovery of more natural compounds to fight infections and cancer.
In this method, drugs are extracted from bacteria that live in dirt. The method exploits the biological antibiotics found in the natural environment—the dirt—where microbes exist.
The process involves diluting a soil sample and placing it on a specialized device. The device is then placed into a box full of the same soil the sample came from, thereby tricking the bacteria into growing into a colony in its natural environment. The method may help resolve two significant issues in global health: the increase in infections that resist commonly used drugs and the lack of new antibiotics to replace those that are no longer effective.
Researchers have discovered a powerful new antibiotic, teixobactin, using an unusual method.
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- High Symptom Burden With Polycythemia Vera Linked to QoL Impairment
- Bioimpedence Spectroscopy Improves Early Detection of Breast Cancer-Related Lymphedema in At-Risk Patients
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- MRD Negativity Associated With Prolonged Survival in Myeloma
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Study Assesses Efficacy of Ramucirumab in HCC by Child-Pugh Score
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Patient Navigation Reduces Delays in Diagnostic Resolution
- Fee-for-service Medicare Plans Linked to Improved Care During Last Year of Life
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|